BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Clovis Oncology Poised for IPO, Targets $13 to $15 Per Share


11/2/2011 7:03:57 AM

Denver Business Journal by Greg Avery, Reporter

Clovis Oncology Inc., a biotech drug research company, has priced its shares at between $13 and $15 for an initial public offering that could take place any day.

The Boulder-based startup filed a prospectus stating the price range for 9.3 million shares it plans to sell.

Clovis Oncology plans to go public on the NASDAQ Global Market under the symbol CLVS.

The company estimates its net proceeds, after underwriting expenses are paid, being $121.2 million if its IPO shares sell for the mid-range price of $14 each.

Clovis plans to use the money for clinical trials and other operating expenses.

The filing projects the maximum amount its IPO is likely to raise being $160.4 million, including the potential sale of over-allotment shares to companies handling the offering.

The company’s investors and founding executives are interested in buying $50.6 million worth of Clovis’ shares in the IPO, the prospectus said.

The 44-employee company was form­ed in 2009 by veteran biotech entrepreneur Pat Mahaffy. It launched with $146 million in backing from several venture capital and investment groups, and from its founding executives.

The company filed paperwork preparing for its IPO in June. Its mid-summer filings hinted that it wanted to complete its initial offering close to Oct. 1.

Unusually high volatility in the stock market in late has given way to relatively more regular gains in recent weeks.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES